Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Survival patterns and cancer determinants in families with myotonic dystrophy type 1.

Best AF, Hilbert JE, Wood L, Martens WB, Nikolenko N, Marini-Bettolo C, Lochmüller H, Rosenberg PS, Moxley RT 3rd, Greene MH, Gadalla SM.

Eur J Neurol. 2018 Jul 27. doi: 10.1111/ene.13763. [Epub ahead of print]

PMID:
30051542
2.

Author response: High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

Hilbert JE, Thornton CA, Moxley RT 3rd.

Neurology. 2018 Apr 24;90(17):814. doi: 10.1212/WNL.0000000000005370. No abstract available.

PMID:
29686124
3.

Cross-sectional study to estimate the prevalence of enterohaemorrhagic Escherichia coli on hides of market beef cows at harvest.

Schneider LG, Stromberg ZR, Lewis GL, Moxley RA, Smith DR.

Zoonoses Public Health. 2018 Mar 25. doi: 10.1111/zph.12468. [Epub ahead of print]

PMID:
29577661
4.

A four-season longitudinal study of enterohaemorrhagic Escherichia coli in beef cow-calf herds in Mississippi and Nebraska.

Schneider LG, Lewis GL, Moxley RA, Smith DR.

Zoonoses Public Health. 2018 Aug;65(5):552-559. doi: 10.1111/zph.12465. Epub 2018 Mar 24.

PMID:
29573177
5.

Health profile of a cohort of adults with Duchenne muscular dystrophy.

Pandya S, James KA, Westfield C, Thomas S, Fox DJ, Ciafaloni E, Moxley RT.

Muscle Nerve. 2018 Aug;58(2):219-223. doi: 10.1002/mus.26129. Epub 2018 Mar 30.

PMID:
29543994
6.

Tellurite Resistance in Shiga Toxin-Producing Escherichia coli.

Lewis GL, Jorgensen QR, Loy JD, Moxley RA.

Curr Microbiol. 2018 Jun;75(6):752-759. doi: 10.1007/s00284-018-1444-x. Epub 2018 Feb 8.

PMID:
29423730
7.

Myotonic dystrophy patient preferences in patient-reported outcome measures.

Heatwole C, Johnson N, Dekdebrun J, Dilek N, Eichinger K, Hilbert J, Luebbe E, Martens W, Mcdermott MP, Thornton C, Moxley R.

Muscle Nerve. 2018 Jan 12. doi: 10.1002/mus.26066. [Epub ahead of print]

PMID:
29328504
8.

Galactooligosaccharide supplementation provides protection against Citrobacter rodentium-induced colitis without limiting pathogen burden.

Kittana H, Quintero-Villegas MI, Bindels LB, Gomes-Neto JC, Schmaltz RJ, Segura Munoz RR, Cody LA, Moxley RA, Hostetter J, Hutkins RW, Ramer-Tait AE.

Microbiology. 2018 Feb;164(2):154-162. doi: 10.1099/mic.0.000593. Epub 2017 Dec 19.

PMID:
29256851
9.

Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial.

Sacktor N, Skolasky RL, Moxley R, Wang S, Mielke MM, Munro C, Steiner J, Nath A, Haughey N, McArthur J.

J Neurovirol. 2018 Feb;24(1):16-27. doi: 10.1007/s13365-017-0587-z. Epub 2017 Oct 23.

PMID:
29063516
10.

Culture-Based Quantification with Molecular Characterization of Non-O157 and O157 Enterohemorrhagic Escherichia coli Isolates from Rectoanal Mucosal Swabs of Feedlot Cattle.

Stromberg ZR, Lewis GL, Schneider LG, Erickson GE, Patel IR, Smith DR, Moxley RA.

Foodborne Pathog Dis. 2018 Jan;15(1):26-32. doi: 10.1089/fpd.2017.2326. Epub 2017 Oct 12.

PMID:
29022742
11.

High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

Hilbert JE, Barohn RJ, Clemens PR, Luebbe EA, Martens WB, McDermott MP, Parkhill AL, Tawil R, Thornton CA, Moxley RT 3rd; National Registry Scientific Advisory Committee/Investigators.

Neurology. 2017 Sep 26;89(13):1348-1354. doi: 10.1212/WNL.0000000000004420. Epub 2017 Aug 30.

12.

A randomized controlled trial to evaluate the effects of dietary fibre from distillers grains on enterohemorrhagic Escherichia coli detection from the rectoanal mucosa and hides of feedlot steers.

Schneider LG, Klopfenstein TJ, Stromberg ZR, Lewis GL, Erickson GE, Moxley RA, Smith DR.

Zoonoses Public Health. 2018 Feb;65(1):124-133. doi: 10.1111/zph.12379. Epub 2017 Jul 28.

PMID:
28755469
13.

Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation-Sponsored Workshop.

Hesterlee S, Amur S, Bain LJ, Carulli J, Clarke S, Day JW, Gagnon C, Hagerman K, Heatwole C, Johnson NE, Moxley R 3rd, Patel N, Thornton C, Kessel W, White M.

Ther Innov Regul Sci. 2017 Jul;51(4):516-522. doi: 10.1177/2168479016683988. Epub 2017 Feb 9.

PMID:
30227044
14.

Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.

Gadalla SM, Hilbert JE, Martens WB, Givens S, Moxley RT 3rd, Greene MH.

Eur J Neurol. 2017 May;24(5):713-718. doi: 10.1111/ene.13276. Epub 2017 Mar 20.

15.
16.

Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Fitzgerald BP, Conn KM, Smith J, Walker A, Parkhill AL, Hilbert JE, Luebbe EA, Moxley RT III.

J Neurol. 2016 Dec;263(12):2528-2537. Epub 2016 Oct 12.

17.

Development of 11-Plex MOL-PCR Assay for the Rapid Screening of Samples for Shiga Toxin-Producing Escherichia coli.

Woods TA, Mendez HM, Ortega S, Shi X, Marx D, Bai J, Moxley RA, Nagaraja TG, Graves SW, Deshpande A.

Front Cell Infect Microbiol. 2016 Aug 31;6:92. doi: 10.3389/fcimb.2016.00092. eCollection 2016.

18.

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.

Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT 3rd, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM.

Neurology. 2016 Nov 15;87(20):2123-2131. Epub 2016 Aug 26.

19.

Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Topaloglu H, Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M.

Neurology. 2016 Jul 12;87(2):238. doi: 10.1212/01.wnl.0000489553.99227.18. No abstract available.

PMID:
27402942
20.

Comparison of Agar Media for Detection and Quantification of Shiga Toxin-Producing Escherichia coli in Cattle Feces.

Stromberg ZR, Lewis GL, Moxley RA.

J Food Prot. 2016 Jun;79(6):939-49. doi: 10.4315/0362-028X.JFP-15-552.

PMID:
27296597
21.

Membrane Insertion for the Detection of Lipopolysaccharides: Exploring the Dynamics of Amphiphile-in-Lipid Assays.

Stromberg LR, Hengartner NW, Swingle KL, Moxley RA, Graves SW, Montaño GA, Mukundan H.

PLoS One. 2016 May 26;11(5):e0156295. doi: 10.1371/journal.pone.0156295. eCollection 2016.

22.

Presence of pathogenic Escherichia coli is correlated with bacterial community diversity and composition on pre-harvest cattle hides.

Chopyk J, Moore RM, DiSpirito Z, Stromberg ZR, Lewis GL, Renter DG, Cernicchiaro N, Moxley RA, Wommack KE.

Microbiome. 2016 Mar 22;4:9. doi: 10.1186/s40168-016-0155-4.

23.

Prevalence and Level of Enterohemorrhagic Escherichia coli in Culled Dairy Cows at Harvest.

Stromberg ZR, Lewis GL, Aly SS, Lehenbauer TW, Bosilevac JM, Cernicchiaro N, Moxley RA.

J Food Prot. 2016 Mar;79(3):421-31. doi: 10.4315/0362-028X.JFP-15-368.

24.
25.

Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).

Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, Luebbe E, Martens W, McDermott MP, Quinn C, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd.

Neurology. 2015 Dec 15;85(24):2136-46. doi: 10.1212/WNL.0000000000002225. Epub 2015 Nov 18.

26.

Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.

Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT 3rd, Heatwole CR.

Dev Med Child Neurol. 2016 Jul;58(7):698-705. doi: 10.1111/dmcn.12948. Epub 2015 Oct 28.

27.

Prevalence of Enterohemorrhagic Escherichia coli O26, O45, O103, O111, O121, O145, and O157 on Hides and Preintervention Carcass Surfaces of Feedlot Cattle at Harvest.

Stromberg ZR, Baumann NW, Lewis GL, Sevart NJ, Cernicchiaro N, Renter DG, Marx DB, Phebus RK, Moxley RA.

Foodborne Pathog Dis. 2015 Jul;12(7):631-8. doi: 10.1089/fpd.2015.1945. Epub 2015 May 27.

PMID:
26125496
28.

Peri- and Postharvest Factors in the Control of Shiga Toxin-Producing Escherichia coli in Beef.

Moxley RA, Acuff GR.

Microbiol Spectr. 2014 Dec;2(6). doi: 10.1128/microbiolspec.EHEC-0017-2013. Review.

PMID:
26104455
29.

Purification and characterization of lipopolysaccharides from six strains of non-O157 Shiga toxin-producing Escherichia coli.

Stromberg LR, Stromberg ZR, Banisadr A, Graves SW, Moxley RA, Mukundan H.

J Microbiol Methods. 2015 Sep;116:1-7. doi: 10.1016/j.mimet.2015.06.008. Epub 2015 Jun 18.

PMID:
26093258
30.

Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, Mcdermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd.

Muscle Nerve. 2016 Feb;53(2):183-90. doi: 10.1002/mus.24725. Epub 2015 Dec 29.

31.

Comparison of Enrichment Broths for Supporting Growth of Shiga Toxin-Producing Escherichia coli.

Stromberg ZR, Lewis GL, Marx DB, Moxley RA.

Curr Microbiol. 2015 Aug;71(2):214-9. doi: 10.1007/s00284-015-0824-8. Epub 2015 Apr 28.

PMID:
25917502
32.

Relationship between heat-labile enterotoxin secretion capacity and virulence in wild type porcine-origin enterotoxigenic Escherichia coli strains.

Wijemanne P, Xing J, Berberov EM, Marx DB, Francis DH, Moxley RA.

PLoS One. 2015 Mar 13;10(3):e0117663. doi: 10.1371/journal.pone.0117663. eCollection 2015.

33.
34.

Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry.

Bora A, Ubaida Mohien C, Chaerkady R, Chang L, Moxley R 4th, Sacktor N, Haughey N, McArthur JC, Cotter R, Nath A, Graham DR.

J Neurovirol. 2014 Oct;20(5):457-65. doi: 10.1007/s13365-014-0263-5. Epub 2014 Jul 24.

35.

Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis.

Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Hilbert JE, Moxley RT 3rd, Landgren O, Greene MH.

PLoS One. 2013 Nov 13;8(11):e79851. doi: 10.1371/journal.pone.0079851. eCollection 2013.

36.

Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.

Heatwole C, Bode R, Johnson N, Dekdebrun J, Dilek N, Heatwole M, Hilbert JE, Luebbe E, Martens W, Mcdermott MP, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley R 3rd.

Muscle Nerve. 2014 Jun;49(6):906-14. doi: 10.1002/mus.24097.

37.

A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder.

Rosenthal LS, Skolasky RL, Moxley RT 4th, Roosa HV, Selnes OA, Eschman A, McArthur JC, Sacktor N.

J Neurovirol. 2013 Oct;19(5):432-41. doi: 10.1007/s13365-013-0195-5. Epub 2013 Oct 1.

38.

Splicing biomarkers of disease severity in myotonic dystrophy.

Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT 3rd, Thornton CA.

Ann Neurol. 2013 Dec;74(6):862-72. doi: 10.1002/ana.23992.

39.

Stochastic simulation model comparing distributions of STEC O157 faecal shedding prevalence between cattle vaccinated with type III secreted protein vaccines and non-vaccinated cattle.

Vogstad AR, Moxley RA, Erickson GE, Klopfenstein TJ, Smith DR.

Zoonoses Public Health. 2014 Jun;61(4):283-9. doi: 10.1111/zph.12069. Epub 2013 Jul 5.

PMID:
23826923
40.

Diagnostic odyssey of patients with myotonic dystrophy.

Hilbert JE, Ashizawa T, Day JW, Luebbe EA, Martens WB, McDermott MP, Tawil R, Thornton CA, Moxley RT 3rd.

J Neurol. 2013 Oct;260(10):2497-504. doi: 10.1007/s00415-013-6993-0. Epub 2013 Jun 27.

41.

Assessment of heterogeneity of efficacy of a three-dose regimen of a type III secreted protein vaccine for reducing STEC O157 in feces of feedlot cattle.

Vogstad AR, Moxley RA, Erickson GE, Klopfenstein TJ, Smith DR.

Foodborne Pathog Dis. 2013 Aug;10(8):678-83. doi: 10.1089/fpd.2012.1374. Epub 2013 May 21.

PMID:
23692077
42.

Development of a genomic DNA reference material panel for myotonic dystrophy type 1 (DM1) genetic testing.

Kalman L, Tarleton J, Hitch M, Hegde M, Hjelm N, Berry-Kravis E, Zhou L, Hilbert JE, Luebbe EA, Moxley RT 3rd, Toji L.

J Mol Diagn. 2013 Jul;15(4):518-25. doi: 10.1016/j.jmoldx.2013.03.008. Epub 2013 May 13.

43.

The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms.

Johnson NE, Luebbe E, Eastwood E, Chin N, Moxley RT 3rd, Heatwole CR.

J Child Neurol. 2014 Jul;29(7):983-6. doi: 10.1177/0883073813484804. Epub 2013 Apr 22.

PMID:
23611887
44.

Both enzymatic and non-enzymatic properties of heat-labile enterotoxin are responsible for LT-enhanced adherence of enterotoxigenic Escherichia coli to porcine IPEC-J2 cells.

Fekete PZ, Mateo KS, Zhang W, Moxley RA, Kaushik RS, Francis DH.

Vet Microbiol. 2013 Jun 28;164(3-4):330-5. doi: 10.1016/j.vetmic.2013.02.019. Epub 2013 Feb 28.

PMID:
23517763
45.

New insights about the incidence, multisystem manifestations, and care of patients with congenital myotonic dystrophy.

Hilbert JE, Johnson NE, Moxley RT 3rd.

J Pediatr. 2013 Jul;163(1):12-4. doi: 10.1016/j.jpeds.2013.02.022. Epub 2013 Mar 16. No abstract available.

PMID:
23507025
46.

Protection of piglets against enteric colibacillosis by intranasal immunization with K88ac (F4ac) fimbriae and heat labile enterotoxin of Escherichia coli.

Lin J, Mateo KS, Zhao M, Erickson AK, Garcia N, He D, Moxley RA, Francis DH.

Vet Microbiol. 2013 Mar 23;162(2-4):731-9. doi: 10.1016/j.vetmic.2012.09.025. Epub 2012 Oct 3.

PMID:
23089483
47.

A call for transparent reporting to optimize the predictive value of preclinical research.

Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD.

Nature. 2012 Oct 11;490(7419):187-91. doi: 10.1038/nature11556.

48.

Inverse relationship between heat stable enterotoxin-b induced fluid accumulation and adherence of F4ac-positive enterotoxigenic Escherichia coli in ligated jejunal loops of F4ab/ac fimbria receptor-positive swine.

Erume J, Wijemanne P, Berberov EM, Kachman SD, Oestmann DJ, Francis DH, Moxley RA.

Vet Microbiol. 2013 Jan 25;161(3-4):315-24. doi: 10.1016/j.vetmic.2012.07.048. Epub 2012 Aug 3.

PMID:
22901529
49.

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R 3rd.

Neurology. 2012 Jul 24;79(4):348-57. doi: 10.1212/WNL.0b013e318260cbe6. Epub 2012 Jul 11. Erratum in: Neurology. 2012 Sep 25;79(13):1411.

50.

Correlates of tumor development in patients with myotonic dystrophy.

Das M, Moxley RT 3rd, Hilbert JE, Martens WB, Letren L, Greene MH, Gadalla SM.

J Neurol. 2012 Oct;259(10):2161-6. doi: 10.1007/s00415-012-6476-8. Epub 2012 May 23.

Supplemental Content

Loading ...
Support Center